2.674USD-4.85%Mkt Cap: 17.04M USDP/E: —Last update: 2026-05-26
Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiot…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap17.04M USD
Enterprise Value14.02M USD
Revenue (TTM)—
Gross Profit-3.29M USD
Net Income (TTM)-4.95M USD
Revenue/Share—
Last Price2.674 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees8
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.58
PEG—
EV/EBITDA-1.42
EV/Revenue—
P/S—
P/B4.48
EPS (TTM)-0.79
EPS (Forward)-0.77
52W Range
2.6301% of range10.80
52W High10.80 USD
52W Low2.630 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-125.98%
ROA-35.23%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-8.55M USD
CapEx (TTM)1.00K USD
FCF Margin—
FCF Yield-24.72%
Net Debt-3.57M USD
Net Debt/EBITDA0.36
Balance Sheet
Debt/Equity0.04
Current Ratio1.19
Quick Ratio0.98
Book Value/Sh0.6160 USD
Cash/Share0.5880 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:5
Split DateAug 28, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.6.37M
Float3.38M
Insiders35.38%
Institutions2.70%
Short Interest
Short Ratio3.2d
Short % Float1.72%
Short % Out.0.82%
Shares Short52.38K
Short (prev mo.)57.66K
Technical
SMA 503.779 (-29.2%)
SMA 2004.619 (-42.1%)
Beta3.62
S&P 52W Chg28.31%
Avg Vol (30d)15.93K
Avg Vol (10d)14.23K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—